RhoA-Rho Associated Kinase Signaling Leads to Renin-Angiotensin System Imbalance and Angiotensin Converting Enzyme 2 Has a Protective Role in Acute Pulmonary Embolism.

Xiaoling Xu,Liuhong Shi,Xiuqing Ma,Hua Su,Guofeng Ma,Xiaohong Wu,Kejing Ying,Ruifeng Zhang

DOI: https://doi.org/10.1016/j.thromres.2019.02.016

IF: 10.407

2019-01-01

Thrombosis Research

Abstract:INTRODUCTION:Acute pulmonary embolism (APE) is a cardiovascular disease with high morbidity and mortality. Although the anatomical obstruction of the pulmonary vascular bed initiates APE, recent studies have suggested that vasoconstrictors in the renin-angiotensin system (RAS) play a role in the severity of APE.MATERIALS AND METHODS:We performed a 5-year retrospective clinical study to analyze the key RAS components in APE patients, including angiotensin converting enzyme (ACE), ACE2, angiotensin II (Ang II) and angiotensin 1-7(Ang(1-7)). The role of RhoA-Rho associated kinase (ROCK) signaling in regulating RAS vasoconstrictors was detected in rat pulmonary artery endothelial cells and in an APE rat model.RESULTS:In clinical study, we found that the levels of RAS vasoconstrictors were correlated with the clinical classification of APE patients, ACE and Ang II were unregulated, whereas ACE2 and Ang(1-7) were downregulated in the high-risk group compared to the healthy volunteers. In animal study, we found that activated RhoA-ROCK signaling was responsible for the imbalance in RAS vasoconstrictors both in vitro and in vivo, and further evidence indicated that ROCK inhibitors (Y27632 or HA1077) and an ACE2 activator (Resorcinol naphthalein) restored the dysregulated RAS vasoconstrictors significantly and had a protective role in an APE rat model.CONCLUSIONS:Our study revealed that RhoA-ROCK signaling leads to RAS imbalance in APE patients, and ACE2 activation might be a novel therapeutic target in APE treatment.